Glaukos Medical Corp. is slowly proving its stent used in the treatment of glaucoma can be used as a standalone therapy, dispelling the idea the device must be used in conjunction with cataract procedures. The San Clemente, Calif.-based company, which competes in the Micro-Invasive Glaucoma Surgery (MIGS) space, revealed hard data in the form of a 53 open-angle glaucoma patient study. Results showed that Glaukos' Istent Inject Trabecular Micro-Bypass stent, combined with topical travoprost, delivered a 35 percent reduction in mean intraocular pressure (IOP) to 12.9 millimeters Hg after 18 months of follow-up. The results...
Glaukos Medical Corp. is slowly proving its stent used in the treatment of glaucoma can be used as a standalone therapy, dispelling the idea the device must be used in conjunction with cataract procedures. The San Clemente, Calif.-based company, which competes in the Micro-Invasive Glaucoma Surgery (MIGS) space, revealed hard data in the form of a 53 open-angle glaucoma patient study.
K2M Group Holdings Inc. is launching its Sahara Al Expandable stabilization system, the company's first expandable offering within its interbody portfolio. Sahara adds more ammunition to the Leesburg, Va.-based company's portfolio options and its bid to gain more share in the spine market, which has seen significant consolidation over the past few years. K2M is third in the complex spine market, trailing behind New Brunswick, N.J.-based Johnson & Johnson Corp. and Dublin-based Medtronic plc. K2M's Sahara has a multiscrew fixation, designed to provide stability to the anterior column, while featuring a comprehensive range of lordotic...
K2M Group Holdings Inc. is launching its Sahara Al Expandable stabilization system, the company's first expandable offering within its interbody portfolio. Sahara adds more ammunition to the Leesburg, Va.-based company's portfolio options and its bid to gain more share in the spine market, which has seen significant consolidation over the past few years. K2M is third in the complex spine market, trailing behind New Brunswick, N.J.-based Johnson & Johnson Corp. and Dublin-based Medtronic plc.
Perkinelmer Inc. has set its sights on beefing up its diagnostics offerings with a proposal to acquire Euroimmun Medical Laboratory Diagnostics AG, a private company, for $1.3 billion. If the deal goes through, then the Waltham, Mass.-based company could expand its reach into the autoimmune and allergy diagnostic markets. Shares of Perkinelmer (NYSE:PKI) jumped about 6.5 percent during Monday trade, opening at 64.75 and closing at $67.73. Acquiring Lübeck, Germany-based Euroimmun would also give Perkinelmer great inroads into the China market. Sales in China account for about 45 percent of the $310 million in revenue...
Perkinelmer Inc. has set its sights on beefing up its diagnostics offerings with a proposal to acquire Euroimmun Medical Laboratory Diagnostics AG, a private company, for $1.3 billion. If the deal goes through, then the Waltham, Mass.-based company could expand its reach into the autoimmune and allergy diagnostic markets.
